Antibodies and chimeric antigen receptors specific for B-cell maturation antigen

US11623961B2 · kind B2 · utility

Assignee

• Juno Therapeutics, Inc. · US

Inventors

• Blythe SATHER · South San Francisco, US
• Steven M. Shamah · Acton, US
• Yan Chen · Santa Clara, US
• Rebecca Wu · Seattle, US
• Collin HAUSKINS · Seattle, US
• Csaba Pazmany · Belmont, US
• Jui Dutta-Simmons · Framingham, US
• Kimberly HARRINGTON · Seattle, US

Key dates

• Filing date: Nov 1, 2018
• Grant date: Apr 11, 2023
• Expiry date: Dec 22, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/622
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and chimeric receptors comprising the anti-BCMA binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-BCMA antibodies or antigen-binding fragments thereof specifically bind to BCMA-1. Among the anti-BCMA antibodies are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs or BCMA-binding molecules and uses thereof such as in adoptive cell therapy.